Positive Phase III results for Actelion's insomnia drug marred by safety concerns
This article was originally published in Scrip
Executive Summary
Actelion's first-in-class insomnia drug almorexant met its primary endpoint in a Phase III trial, show top-line data, demonstrating superiority over placebo on wake after sleep onset (WASO). Perhaps driven by safety concerns, however, the company's share price was down nearly 5% in early morning trading to CHF55.50 ($53.20) on the Swiss stock exchange.